Mack Roach and Martin Spahn on 'Oligometastases: RP is experimental and should only be done in the context of a prospective clinical trial’ versus 'RP and SBRT to bone disease is a reasonable management strategy for men with oligomets' - STOP 6

Dr. Mack Roach and Dr. Martin Spahn presented a debate on “Oligometastases: RP Is Experimental and Should Only Be Done in the Context of a Prospective Clinical Trial” versus “RP and SBRT to Bone Disease Is a Reasonable Management Strategy for Men with Oligomets” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6)

Mack Roach III, MD

Martin Spahn, MD, currently Senior Consultant at the Department of Urology at the Inselspital Bern, University Hospital, Bern, Switzerland. Dr. Spahn is member of several scientific societies, including AUA, EAU. He serves as member of the Steering Committee of the Genito-Urinary Group of the EORTC since 2013. He is PI (Principal Investigator) of a large translational Research project (SPECTApros), an EORTC Reseach platform. Dr. Spahn is a reviewer for several journals including European Urology, British Medical Journal, Journal of Urology and serves as a grant reviewer for several scientific organisations in europe including Cancer Research UK, German Cancer League and Swiss National Fund. He received several awards for his translational resarch in high risk Prostate Cancer including the Prostate Cancer Research Award of the EAU in 2015 and the Urological Oncology Award of the EAU in 2011.